Home
About Us
FAQ
Contact Us
Media Tools
ExpertConnect App
MyExpertNet
University Partners
Becoming a Partner
Key Organizations
Search Assistance
Help
Expert Profile
Views:
92
Share
QR code
Edit Profile
Brian Stover
Assistant Professor
MD-PEDS-HEMATOLOGY | COLLEGE-MEDICINE
View:
Select
All (all in one)
Research Terms and Keywords
Publications
Network
Websites
Contact
All
Research
Publications
Network
Websites
Contact
Research Terms & Keywords
Research Terms
Pediatrics
Research Projects
Ends
Title
03-2030
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCORP funding)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCORP funding)
CHILDRENS ONCOLOGY GROU
03-2030
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCORP funding)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCORP funding)
NATL INST OF HLTH NC
03-2030
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCTN funding)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCTN funding)
CHILDRENS ONCOLOGY GROU
03-2030
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCTN funding)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCTN funding)
NATL INST OF HLTH NC
02-2030
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
NATL INST OF HLTH NC
02-2030
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >1 to < 31 Years Old With First Relapse
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >1 to < 31 Years Old With First Relapse
NATL INST OF HLTH NC
02-2030
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
NATL INST OF HLTH NC
02-2030
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
CHILDRENS HOSP PHILADELPHI
02-2030
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
NATL INST OF HLTH NC
02-2030
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, And Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (TI-CE) As Firs
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, And Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (TI-CE) As Firs
CHILDRENS ONCOLOGY GROU
02-2030
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, And Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (TI-CE) As Firs
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, And Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (TI-CE) As Firs
NATL INST OF HLTH NC
02-2030
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl
CHILDRENS ONCOLOGY GROU
02-2030
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl
NATL INST OF HLTH NC
02-2030
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
NATL INST OF HLTH NC
02-2030
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ulixertinib in patients with tumors harboring activating MAPK pathway mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ulixertinib in patients with tumors harboring activating MAPK pathway mutations
NATL INST OF HLTH NC
02-2030
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
NATL INST OF HLTH NC
02-2030
ARST1431, A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rh
ARST1431, A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rh
NATL INST OF HLTH NC
02-2030
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
CHILDRENS ONCOLOGY GROU
02-2030
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
NATL INST OF HLTH NC
02-2030
The Effectiveness of Lactobacillus Plantarum (LBP) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
The Effectiveness of Lactobacillus Plantarum (LBP) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
NATL INST OF HLTH NC
02-2030
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
CHILDRENS ONCOLOGY GROU
02-2030
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
NATL INST OF HLTH NC
02-2030
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
CHILDRENS ONCOLOGY GROU
02-2030
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
NATL INST OF HLTH NC
02-2029
A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/=12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/=12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
NATL INST OF HLTH NC
07-2027
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
CHILDRENS ONCOLOGY GROU
07-2027
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NATL INST OF HLTH NC
07-2026
A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors ? ALTE2031
A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors ? ALTE2031
NATL INST OF HLTH NC
02-2026
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
NATL INST OF HLTH NC
02-2026
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
NATL INST OF HLTH NC
02-2026
A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax
A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax
NATL INST OF HLTH NC
02-2026
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
NATL INST OF HLTH NC
02-2026
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer
NATL INST OF HLTH NC
02-2026
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
NATL INST OF HLTH NC
02-2026
A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia
A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia
NATL INST OF HLTH NC
02-2026
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
NATL INST OF HLTH NC
02-2026
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
NATL INST OF HLTH NC
02-2026
Phase 2 Study of DAY101 in Relapsed and Refractory Langerhans Cell Histiocytosis
Phase 2 Study of DAY101 in Relapsed and Refractory Langerhans Cell Histiocytosis
NATL INST OF HLTH NC
02-2026
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
NATL INST OF HLTH NC
02-2026
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic
NATL INST OF HLTH NC
02-2026
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
NATL INST OF HLTH NC
02-2026
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NATL INST OF HLTH NC
02-2026
Pediatric Acute Leukemia (PedAL) Screening Trial ? Developing New Therapies for Relapsed Leukemias
Pediatric Acute Leukemia (PedAL) Screening Trial ? Developing New Therapies for Relapsed Leukemias
NATL INST OF HLTH NC
02-2026
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
NATL INST OF HLTH NC
02-2026
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
NATL INST OF HLTH NC
02-2026
A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/=12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/=12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
NATL INST OF HLTH NC
02-2026
COG Chair Grant
COG Chair Grant
NATL INST OF HLTH NC
02-2026
ACCL1633, The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
ACCL1633, The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
NATL INST OF HLTH NC
02-2026
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
CHILDRENS ONCOLOGY GROU
02-2026
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
NATL INST OF HLTH NC
02-2026
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
CHILDRENS ONCOLOGY GROU
02-2026
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
NATL INST OF HLTH NC
01-2026
Randomized phase 2/3 trial of vincristine-irinotecan-regorafenib in combination with vincristine-doxorubicin-cyclophosphamide (VDC) and ifosfamide-etoposide (IE) in patients with newly diagnosed metastatic Ewing sarcoma
Randomized phase 2/3 trial of vincristine-irinotecan-regorafenib in combination with vincristine-doxorubicin-cyclophosphamide (VDC) and ifosfamide-etoposide (IE) in patients with newly diagnosed metastatic Ewing sarcoma
NATL INST OF HLTH NC
09-2025
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
NATL INST OF HLTH NC
08-2025
A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
NATL INST OF HLTH NC
06-2025
A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
NATL INST OF HLTH NC
05-2025
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
NATL INST OF HLTH NC
05-2025
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
NATL INST OF HLTH NC
03-2025
Ultrasound elastogram assessment of liver fibrosis in children and adolescents/young adults (AYA) receiving chemotherapy or allogeneic bone marrow transplantation, and identification of risk factors for liver injury
Ultrasound elastogram assessment of liver fibrosis in children and adolescents/young adults (AYA) receiving chemotherapy or allogeneic bone marrow transplantation, and identification of risk factors for liver injury
LIVE LIKE BELLA PEDIATRIC CANCER RESEARC
03-2025
ARST2031: A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Mai
ARST2031: A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Mai
NATL INST OF HLTH NC
Publications
OpenAlex
Search Engines
Last updated on 8/17/26. See our
OpenAlex FAQ
for more about this data.
Search Google Scholar for Brian Stover
OpenAlex Works Search
Co-Investigator Network
Inactive Expert
William Slayton
Professor
University of Florida
Md-Peds-Hematology, College-Medicine
Tung Wynn
Clinical Associate Professor
University of Florida
Md-Peds-Hematology, College-Medicine
twynn@ufl.edu
Jatinder Lamba
Associate Dean For Research and Graduate Education; Professor and The Frank A. Duckworth Eminent Scholar Chair
University of Florida
Ph-Pharmtherapy Trnsl Rsch, College-Pharmacy
jatinderklamba@ufl.edu
Priya Sharma
Clinical Associate Professor
University of Florida
Md-Radiology-Pediatric, College-Medicine
sharpg@radiology.ufl.edu
Inactive Expert
Giselle Moore-Higgs
Clinical Programs, Asst Dir 4
University of Florida
Md-Cancer Center Clinical Trials, College-Medicine
Expertnet Author Network
Experts within Florida Expertnet that have co-authored works with Brian Stover.
Inactive Expert
Lung-Ji Chang
Professor
University of Florida
Md-Molecular Gentcs - Microbio, College-Medicine
Works Co-Authored: 39
Wallace Sawyer
Professor & Distinguished Teaching Scholar
University of Florida
Eg-Mechanical - Aerospace Eng, College-Engineering
wgsawyer@ufl.edu
Works Co-Authored: 328
Rowan Milner
Chair & Asoc. Professor, Sacs
University of Florida
Vm-Sacs, College Of Veterinary Medicine
milnerr@ufl.edu
Works Co-Authored: 90
Jeffrey Harrison
Professor & Vice Chair Of Education
University of Florida
Md-Pharmacology - Therapeutics, College-Medicine
jharriso@ufl.edu
Works Co-Authored: 162
Inactive Expert
William Slayton
Professor
University of Florida
Md-Peds-Hematology, College-Medicine
Works Co-Authored: 140
Inactive Expert
Jon Dobson
Professor
University of Florida
Eg-Biomedical Engineering, College-Engineering
Works Co-Authored: 48
Kirsten Coleman
Ast Dir, Research Admin
University of Florida
Md-Powell Gene Therapy Center, College-Medicine
kee2000@ufl.edu
Works Co-Authored: 16
Marcia Hodik
Clinical Research Nurse Coordinator
University of Florida
Md-Neurological Surgery, College-Medicine
marcia.hodik@neurosurgery.ufl.edu
Works Co-Authored: 11
Brian Cleaver
Associate Program Director
University of Florida
Md-Neurological Surgery, College-Medicine
bcleaver@ufl.edu
Works Co-Authored: 27
Inactive Expert
Nagheme Thomas
University of Florida
Md-Neuroscience-General, College-Medicine
Works Co-Authored: 24
Matthew Sarkisian
Associate Professor, Program Director Ms in Neuroscience Graduate Program
University of Florida
Md-Neuroscience-General, College-Medicine
msarkisian@ufl.edu
Works Co-Authored: 102
Joanne Lagmay
Professor; Chief; Stop Children's Cancer Of Palm Beach County, Inc. Professorship in Pediatric Oncology
University of Florida
Md-Peds-Hematology, College-Medicine
jplagmay@peds.ufl.edu
Works Co-Authored: 45
Carlos Rinaldi
Prof
University of Florida
Eg-Biomedical Engineering, College-Engineering
carlos.rinaldi@ufl.edu
Works Co-Authored: 252
Tung Wynn
Clinical Associate Professor
University of Florida
Md-Peds-Hematology, College-Medicine
twynn@ufl.edu
Works Co-Authored: 33
Duane Mitchell
Director - Uf Clinical and Translational Science Institute; Assistant Vice President For Research - University Of Florida; Associate Dean - Uf College Of Medicine
University of Florida
Md-Neurological Surgery, College-Medicine
duane.mitchell@neurosurgery.ufl.edu
Works Co-Authored: 384
Elias Sayour
Stop Children's Cancer/Bonnie R. Freeman Professor For Pediatric Oncology Research; Assistant Dean
University of Florida
Md-Neurological Surgery, College-Medicine
elias.sayour@neurosurgery.ufl.edu
Works Co-Authored: 170
Jesse Kresak
Chair & Clin Prof
University of Florida
Md-Pathology-General, College-Medicine
jkresak@ufl.edu
Works Co-Authored: 67
Inactive Expert
Loic Deleyrolle
Faculty
University of Florida
Neurosurgery, College-Medicine
Works Co-Authored: 117
Catherine Flores
Associate Professor
University of Florida
Md-Neurological Surgery, College-Medicine
catherine.flores@neurosurgery.ufl.edu
Works Co-Authored: 115
Maryam Rahman
Professor
University of Florida
Md-Neurological Surgery, College-Medicine
maryam.rahman@neurosurgery.ufl.edu
Works Co-Authored: 180
Paul Castillo Caro
Assistant Professor
University of Florida
Md-Peds-Hematology, College-Medicine
castillopa@ufl.edu
Works Co-Authored: 108
Inactive Expert
Natalie Silver
Assistant Professor
University of Florida
Md-Otolaryngology-Head & Neck, College-Medicine
Works Co-Authored: 53
Matthew Cascio
Assistant Professor
University of Florida
Md-Peds-Hematology, College-Medicine
mcascio@ufl.edu
Works Co-Authored: 8
Inactive Expert
Kyle Dyson
Graduate Assistant
University of Florida
Md-Phd Program, College-Medicine
Works Co-Authored: 44
Inactive Expert
Adam Grippin
Pre Doc Fellow
University of Florida
Md-Neurological Surgery, College-Medicine
Works Co-Authored: 69
Bikash Sahay
Research Associate Professor
University of Florida
Vm-Infect Disease & Immunology, College-Veterinary Med
sahayb@ufl.edu
Works Co-Authored: 63
Jianping Huang
Professor
University of Florida
Md-Neurological Surgery, College-Medicine
jianping.huang@neurosurgery.ufl.edu
Works Co-Authored: 84
Ji-Hyun Lee
Professor & Associate Director For Cancer Quantitative Sciences
University of Florida
Phhp-Com Biostatistics, Phhp-Com Integrated Programs
jihyun.lee@ufl.edu
Works Co-Authored: 1045
Kristianna Fredenburg
Associate Professor
University of Florida
Md-Pathology-General, College-Medicine
kfredenburg@pathology.ufl.edu
Works Co-Authored: 62
Inactive Expert
Biljana Horn
Clinical Professor; Stop Children's Cancer/Bonnie R. Freeman Professorship For Pediatric Oncology Research
University of Florida
Md-Peds-Hematology, College-Medicine
Works Co-Authored: 45
Christina Von Roemeling
Ast Prof
University of Florida
Md-Neurological Surgery, College-Medicine
c.vonroemeling@ufl.edu
Works Co-Authored: 85
Ginger Moore
Scientific Laboratory Manager
University of Florida
Md-Neurological Surgery, College-Medicine
ginger.moore@neurosurgery.ufl.edu
Works Co-Authored: 55
Hector Mendez Gomez
Research Associate Scientist
University of Florida
Md-Neurological Surgery, College-Medicine
hector.mendezgomez@neurosurgery.ufl.edu
Works Co-Authored: 3
Ashley Ghiaseddin
Clinical Associate Professor
University of Florida
Md-Neurological Surgery, College-Medicine
ashley.ghiaseddin@neurosurgery.ufl.edu
Works Co-Authored: 72
Timothy Foster
Assistant Professor
University of Florida
Md-Peds-Endocrinology, College-Medicine
tpfoster@ufl.edu
Works Co-Authored: 22
Sheila Carrera-Justiz
Clinical Associate Professor; Neurology Service Chief
University of Florida
Vm-Sacs, College-Veterinary Med
carrerajustiz.s@ufl.edu
Works Co-Authored: 43
Inactive Expert
John Fort
Clinical Associate Professor
University of Florida
Md-Peds-Hematology, College-Medicine
Works Co-Authored: 44
John Ligon
Assistant Professor
University of Florida
Md-Peds-Hematology, College-Medicine
john.ligon@ufl.edu
Works Co-Authored: 82
Inactive Expert
Juan Guan
Co Ast Prof
University of Florida
Ls-Physics-General, College-Liberal Arts Sciences
Works Co-Authored: 2
Leighton Elliott
Assistant Professor
University of Florida
Md-Hematology-Oncology-Oncol, College-Medicine
leightonelliott@ufl.edu
Works Co-Authored: 10
Inactive Expert
Mansi Dalal
Clinical Assistant Professor
University of Florida
Md-Peds-Hematology, College-Medicine
Works Co-Authored: 16
Reem Kashif
Clinical Assistant Professor, Director Of Sickle Cell Disease Program, and Pediatric Clerkship Core Faculty Member
University of Florida
Md-Peds-Hematology, College-Medicine
reema.kashif@ufl.edu
Works Co-Authored: 15
Rachel Moor
Resident
University of Florida
Md-Neurological Surgery, College-Medicine
rachel.moor@neurosurgery.ufl.edu
Works Co-Authored: 16
Jolan Walter
Associate Professor
University of South Florida
Pediatrics, Morsani College Of Medicine
jolanwalter@usf.edu
Works Co-Authored: 273
Warren Alperstein
University of Miami
Pediatrics, Medical
wxa85@miami.edu
Works Co-Authored: 38
Websites
ORCID 0000-0003-4349-7881
OpenAlex Works Search
Search Google Scholar for Brian Stover
Contact Information
bstover@ufl.edu
3522739120
PO Box 100296 GAINESVILLE, FL 32610
Profile QR code
What is this?
Keyword Search
Please enter valid search criteria.
Search
Centers
Experts
Projects
Publications
Speakers
Stories
Technologies
Videos
University
All Universities
Florida A&M University
Florida Atlantic University
Florida Gulf Coast University
Florida Institute of Technology
Florida International University
Florida State University
University of Central Florida
University of Florida
University of Miami
University of North Florida
University of South Florida
University of West Florida
Browse by STEM
Biotechnology
Computer Science
Energy
Engineering
Environmental Sciences
Information Science
Life Sciences
Mathematics
Medical Sciences
Military Sciences
Natural Sciences
Physical Sciences
Plant Sciences
Science
Space Sciences
Technology
Transportation
